|
1
|
Ngo VP, Civen RH, Dassey DE, Davenport D, Mascola L. Using a Point-of-Dispensing Clinic for Prophylaxis of Meningococcal Disease. Biosecur Bioterror 2010; 8:45-51. [DOI: 10.1089/bsp.2009.0026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Van P. Ngo
- Van P. Ngo, MPH, is an Epidemiologist; Rachel H. Civen, MD, MPH, is Physician Specialist; David E. Dassey, MD, MPH, is Senior Physician; Deborah Davenport, RN, MS, is Community Health Services Director; and Laurene Mascola, MD, MPH, is Chief, Acute Communicable Disease Control; all are at the Los Angeles County Department of Public Health, Los Angeles, California. There was no external financial support provided to complete this investigation. Data from this manuscript were presented in part at the
| | - Rachel H. Civen
- Van P. Ngo, MPH, is an Epidemiologist; Rachel H. Civen, MD, MPH, is Physician Specialist; David E. Dassey, MD, MPH, is Senior Physician; Deborah Davenport, RN, MS, is Community Health Services Director; and Laurene Mascola, MD, MPH, is Chief, Acute Communicable Disease Control; all are at the Los Angeles County Department of Public Health, Los Angeles, California. There was no external financial support provided to complete this investigation. Data from this manuscript were presented in part at the
| | - David E. Dassey
- Van P. Ngo, MPH, is an Epidemiologist; Rachel H. Civen, MD, MPH, is Physician Specialist; David E. Dassey, MD, MPH, is Senior Physician; Deborah Davenport, RN, MS, is Community Health Services Director; and Laurene Mascola, MD, MPH, is Chief, Acute Communicable Disease Control; all are at the Los Angeles County Department of Public Health, Los Angeles, California. There was no external financial support provided to complete this investigation. Data from this manuscript were presented in part at the
| | - Deborah Davenport
- Van P. Ngo, MPH, is an Epidemiologist; Rachel H. Civen, MD, MPH, is Physician Specialist; David E. Dassey, MD, MPH, is Senior Physician; Deborah Davenport, RN, MS, is Community Health Services Director; and Laurene Mascola, MD, MPH, is Chief, Acute Communicable Disease Control; all are at the Los Angeles County Department of Public Health, Los Angeles, California. There was no external financial support provided to complete this investigation. Data from this manuscript were presented in part at the
| | - Laurene Mascola
- Van P. Ngo, MPH, is an Epidemiologist; Rachel H. Civen, MD, MPH, is Physician Specialist; David E. Dassey, MD, MPH, is Senior Physician; Deborah Davenport, RN, MS, is Community Health Services Director; and Laurene Mascola, MD, MPH, is Chief, Acute Communicable Disease Control; all are at the Los Angeles County Department of Public Health, Los Angeles, California. There was no external financial support provided to complete this investigation. Data from this manuscript were presented in part at the
| |
Collapse
|
|
2
|
Damiani PC, Nepote AJ, Bearzotti M, Olivieri AC. A Test Field for the Second-Order Advantage in Bilinear Least-Squares and Parallel Factor Analyses: Fluorescence Determination of Ciprofloxacin in Human Urine. Anal Chem 2004; 76:2798-806. [PMID: 15144190 DOI: 10.1021/ac035541w] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The analytical performances of two algorithms, the recently introduced bilinear least-squares (BLLS) and the popular parallel factor analysis (PARAFAC), are compared as regards second-order fluorescence data recorded for the determination of the fluoroquinolone antibiotic ciprofloxacin in human urine samples. The applied chemometric methodologies employ different strategies for exploiting the so-called second-order advantage, which allows one to obtain individual concentrations of calibrated analytes in the presence of any number of uncalibrated (urine) components. Analysis of a spiked urine test set (in the analyte concentration range 0-200 mg L(-1)) showed that BLLS provides results of slightly better quality than PARAFAC. Satisfactory results have been obtained on comparing the concentrations predicted for a series of real urine samples with those furnished by liquid chromatography. The limit of detection of the fluorescence-based methods is approximately 5 mg L(-1).
Collapse
Affiliation(s)
- Patricia C Damiani
- Departamento de Química Analítica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, Rosario (S2002LRK), Argentina
| | | | | | | |
Collapse
|
|
3
|
Abstract
Fluoroquinolone-induced joint/cartilage toxicity has been observed in juvenile animal studies and is species- and dose-specific with canines exhibiting the highest rate of arthralgias. These early observations led to the contraindication of fluoroquinolones in the pediatric population. Despite these recommendations fluoroquinolones continue to be prescribed for select children with difficult-to-treat infections for whom the benefit of quinolone therapy may outweigh the risk of cartilage toxicity. A review of retrospective and prospective safety data of ciprofloxacin-treated children showed that the rates of arthralgia and quinolone-induced cartilage toxicity were low. Episodes of arthralgia were mostly reversible based on published surveillance data in children. Recent data from Bayer's ciprofloxacin clinical trials database found that the incidence of arthralgia in children did not differ between the ciprofloxacin and nonquinolone antimicrobial control groups. The role of fluoroquinolones in the treatment of certain serious infections in children does not appear to be compromised by safety concerns when used appropriately.
Collapse
Affiliation(s)
- Richard Grady
- Department of Urology, The University of Washington Medical Center, Children's Hospital and Regional Medical Center, Seattle 98105, USA.
| |
Collapse
|
|
4
|
Burstein GR, Berman SM, Blumer JL, Moran JS. Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? Clin Infect Dis 2002; 35:S191-9. [PMID: 12353206 DOI: 10.1086/342107] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
The highest rates of reported gonorrhea infections occur among adolescent females aged 15-19 years. Among the Centers for Disease Control and Prevention (CDC)-recommended single-dose gonorrhea treatment regimens, ciprofloxacin, a fluoroquinolone antibiotic, is approximately half the cost of other CDC-recommended oral treatment regimens. Fluoroquinolone use in patients aged <18 years has been limited because of irreversible articular cartilage damage demonstrated in large, weight-bearing joints of young animals. We reviewed the medical literature to assess whether the risks of a single 500-mg dose of ciprofloxacin to treat uncomplicated gonorrhea infection in adolescents appears to outweigh the benefits. We found no reports of irreversible cartilage toxicity or age-associated adverse events in 5236 human children and adolescents (aged 5 days-24 years) treated with a total of 5486 courses of fluoroquinolones.
Collapse
Affiliation(s)
- Gale R Burstein
- Division of HIV and AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
| | | | | | | |
Collapse
|
|
5
|
Abstract
This review emphasises the advances in the development of newer quinolones: their broader antimicrobial activity particularly their increased activity against Pneumococcus and anaerobes; their longer half-life and tissue penetration including activity in cerebrospinal fluid; and their excellent efficacy in respiratory, intra-abdominal, pelvic, and skin and soft tissue infections. Also, considerable progress has been made in our understanding of the development of bacterial resistance to the newer quinolones. Additional advances in quinolone development are likely to provide better compounds for clinical use.
Collapse
Affiliation(s)
- V T Andriole
- Yale University School of Medicine, New Haven, Connecticut 06520-8022, USA
| |
Collapse
|